Related Experiment Video
Updated: Jun 30, 2025
06:33
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
Published on: November 10, 2023
1.2K
Prognostic marker CD27 and its micro-environmental in multiple myeloma
Xinya Wang1, Keyang Luo1, Qiuting Xu1
1Hematology Department, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, People's Republic of China.
BMC Cancer
|March 20, 2024
Summary
Elevated CD27 expression in T cells indicates a poorer prognosis for multiple myeloma (MM) patients. Targeting the CD27-PERK-ATF4 pathway shows promise for MM treatment.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Aberrant expression of Cluster of Differentiation 27 (CD27) in multiple myeloma (MM) facilitates immune evasion via the CD27-CD70 pathway.
- This interaction promotes tumor progression within the tumor microenvironment (TME).
Purpose of the Study:
- To investigate the correlation between CD27 expression and MM prognosis.
- To elucidate the relationship between CD27 and the immune microenvironment in MM.
Main Methods:
- Flow cytometry assessed CD27 expression in T cells from 82 newly diagnosed MM patients.
- Bioinformatics and in vitro experiments explored CD27's role in MM.
Main Results:
- Elevated CD27 in bone marrow T cells is a negative prognostic marker for MM survival.
- CD27 expression is associated with immune response, hematopoietic system, and increased myeloid-derived suppressor cells (MDSCs) and macrophages.
- The PERK-ATF4 signaling pathway mediates CD27 effects in MM.
Conclusions:
- CD27 expression levels are indicative of MM patient prognosis.
- The CD27-PERK-ATF4 pathway presents a potential therapeutic target for MM treatment.
